Cipla
Cipla Ltd.
Mumbai Central
Mumbai 400 008

5th November, 2012

(1) BSE Ltd.
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

Dear Sirs,

Please find enclosed copy of the note displayed on our website www.cipla.com for your reference.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi

Mital Sanghvi
Company Secretary

Encl: as above

Financial Review – Period ended Sep 2012

(Rupees in crore)

	Quarter Ended			Half Year Ended		
	30/09/2012	**30/09/2011**	**% change**	**30/09/2012**	**30/09/2011**	**% change**
Domestic	961.67	847.03	13.5%	1931.34	1590.65	21.4%
Exports - Formulations	1038.93	751.58	38.2%	1849.04	1410.45	31.1%
APIs & others	173.77	159.48	9.0%	342.23	330.8	3.5%
Total Exports	1212.70	911.06	33.1%	2191.27	1741.25	25.8%
% of exports to total sales	55.8%	51.8%		53.2%	52.3%	
Total Sales	2174.37	1758.09	23.7%	4122.61	3331.90	23.7%
Other operating income						
Technology knowhow/fees	4.64	7.77		10.39	17.60	
Others	41.33	30.06		76.39	52.65	
Total	45.97	37.83	21.5%	86.78	70.25	23.5%
Income from Operations	2220.34	1795.92	23.6%	4209.39	3402.15	23.7%
Material Cost	788.60	711.65		1521.02	1379.88	
% to total sales	36.3%	40.5%		36.9%	41.4%	
Operating margin	676.95	429.25	57.7%	1216.80	790.12	54.0%
% to income from operations	30.5%	23.9%		28.9%	23.2%	
Profit before tax	661.77	393.92	68.0%	1180.77	713.81	65.4%
% to income from operations	29.8%	21.9%		28.1%	21.0%	
Profit after tax	500.01	308.97	61.8%	900.77	562.31	60.2%
% to income from operations	22.5%	17.2%		21.4%	16.5%	

During the quarter, the company posted a growth of about 24% in income from operations. Domestic sales grew by more than 13% and export sales grew by more than 33%. Operating margins and profits after tax have increased by about 58% and 62% respectively on a year-on-year basis.

Material cost has decreased by 4% mainly on account of changes in product mix viz. lower proportion of anti-retrovirals and higher contribution of anti-depressant segment (Escitalopram) coupled with increased realizations. As a result, operating margins have also increased by more than 6%.

The increase in staff cost of Rs. 55 cr is due to annual increments and increase in manpower. Other expenditure has increased by Rs. 42 cr for the quarter mainly on account of increase in travel expenses, marketing expenditure, professional charges, etc. Tax for the current quarter has increased due to higher profits.